Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
Po-Ying Chan-Hui, Bellevue, WA (US); Katherine Doores, San Diego, CA (US); Michael Huber, Zurich (CH); Stephen Kaminsky, Bronx, NY (US); Steven Frey, Redmond, WA (US); Ole Olsen, Everett, WA (US); Jennifer Mitcham, Redmond, WA (US); Matthew Moyle, Redmond, WA (US); Sanjay K. Phogat, Frederick, MD (US); Dennis R. Burton, La Jolla, CA (US); Laura Majorie Walker, San Diego, CA (US); Pascal Raymond Georges Poignard, San Diego, CA (US); Wayne Koff, Stony Brook, NY (US); and Melissa Danielle De Jean De St. Marcel Simek-Lemos, Brooklyn, NY (US)
Assigned to International AIDS Vaccine Initiative, Inc., New York, NY (US); The Scripps Research Institute, La Jolla, CA (US); and Theraclone Sciences Inc., Seattle, WA (US)
Filed by INTERNATIONAL AIDS VACCINE INITIATIVE, INC., New York, NY (US); THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA (US); and THERACLONE SCIENCES INC., Seattle, WA (US)
Filed on Aug. 18, 2023, as Appl. No. 18/452,002.
Application 18/452,002 is a continuation of application No. 17/376,276, filed on Jul. 15, 2021, granted, now 11,845,789.
Application 17/376,276 is a continuation of application No. 16/591,175, filed on Oct. 2, 2019, granted, now 11,319,362, issued on May 3, 2022.
Application 16/591,175 is a continuation of application No. 15/701,679, filed on Sep. 12, 2017, granted, now 10,836,811, issued on Nov. 17, 2020.
Application 15/701,679 is a continuation of application No. 15/152,630, filed on May 12, 2016, granted, now 10,087,239, issued on Oct. 2, 2018.
Application 15/152,630 is a continuation of application No. 13/780,776, filed on Feb. 28, 2013, granted, now 9,464,131, issued on Oct. 11, 2016.
Application 13/780,776 is a continuation in part of application No. PCT/US2011/049880, filed on Aug. 31, 2011.
Claims priority of provisional application 61/515,548, filed on Aug. 5, 2011.
Claims priority of provisional application 61/476,978, filed on Apr. 19, 2011.
Claims priority of provisional application 61/386,940, filed on Sep. 27, 2010.
Claims priority of provisional application 61/378,604, filed on Aug. 31, 2010.
Prior Publication US 2024/0132578 A1, Apr. 25, 2024
1. A non-naturally occurring PGT-124 monoclonal antibody comprising (a) a light chain variable region comprising three complementarity determining regions having the amino acid sequences of SEQ ID NOs: 415, 151, and 416 and (b) a heavy chain variable region comprising three complementarity determining regions having the amino acid sequences of SEQ ID NOs: 406, 407, and 408, wherein the CDRs are per Kabat definition, wherein the antibody comprises an engineered Fc region incorporating a salvage receptor binding epitope, thereby exhibiting increased serum half-life through enhanced interaction with the neonatal Fc receptor (FcRn).